LG Reviewed 21-Inch Diagnostic Monitor Amid Full Display Line Showcasedat RSNA 2023

At RSNA 2023, LG Business Solutions USA will unveil an advanced new 21-inch 5MP diagnostic monitor, while showcasing its full line of displays specially designed for radiology, mammography, diagnostics, clinical review and surgical imagery, along with digital X-ray detectors.

According to Stephen K. Hu, LG Business Solutions USA’s head of medical displays, RSNA attendees who visit LG’s booth #1361 can see how its wide variety of medical displays increase flexibility and choice while delivering leading performance and capabilities for various medical settings.

“LG’s expanded family of medical monitors and devices offers hospitals and medical professionals more options to outfit their spaces with precisely the type and size of monitor they need to review medical imagery and make diagnoses,” Hu said. “In addition to the medical devices, our booth also showcases the convenience of LG UltraPC laptops and the eye-catching power of LG All-in-One DVLED displays for conference spaces or public-facing needs, reinforcing the strength of LG’s vast product catalog to serve virtually every need.”

Attendees who visit LG’s booth will be able to learn about 20 unique products, led by the upcoming 21.5-inch 5MP Diagnostic Monitor (model 21HQ613D) which offers a 2048×2560 IPS display, 1800:1 contrast ratio and special features such as an auto luminance sensor and Light Box Mode with external lighting that increases readability in darkened environments. This advanced diagnostic monitor also offers daisy chain capability to connect two monitors to a single PC and includes five hot keys for rapid switching between screen modes.

It’s the perfect addition to LG’s diagnostic display lineup, especially for showcasing Mammographic images. The new monitor will be showcased alongside LG’s flagship display for Mammographic images: the 31HN713D, which provides a solution for side-by-side viewing with a 12MP resolution. As a result, it can accommodate dual 5MP Mammographic images on its 31-inch (3:2) IPS display.

Throughout the booth, attendees can experience the LG difference as they view 4K diagnostic, surgical and clinical review monitors ranging from 21- to 32 inches, along with a 55-inch 4K IPS surgical monitor. Among the products on display is a 24-inch 2MP IPS monitor that is pending FDA 510(K) clearance and is not yet available for commercial sale in the United States.

Buyers will also have the opportunity to see LG’s line of powerful and cost-efficient portable X-ray detectors with oxide and amorphous silicon TFT to ensure clear images, with each of the three model sizes offering up to 300 images per charge.

LG’s 75-inch CreateBoard multi-touch digital whiteboard, Box-Type Thin Client PC, DualUp 16:18 IPS monitors and UltraPC laptops – even the cutting-edge LG CLOi ServeBot 3.0 autonomous delivery robot – will also be on display to show the breadth of LG’s solutions on offer to assist the functional needs of a hospital environment.

Visitors will easily be able to spot the booth thanks to the giant 136-inch (diagonal) LG direct-view light-emitting diode (DVLED) display demonstrating the power of the large, bright displays to attract attention and provide an excellent canvas for conference room presentations or virtual collaborations in today’s state-of-the-art radiological centers and medical complexes.

“LG is fully committed to delivering the highest quality displays and products for diagnostics, detection and medical review needs to help hospitals and medical professionals deliver exceptional care,” Hu said. “As our catalog of specialized devices grows, we will continue to deliver forward-looking solutions based on the constant advances in medical care and providers’ expectations.”

For more information about LG’s medical products that will be on display at RSNA 2023, click here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”